Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects

Circulation

Volumn 132, Issue 19, 2015, Pages 1825-1833

  Baudrand, Rene ^a,b   Pojoga, Luminita H ^a   Vaidya, Anand ^a   Garza, Amanda E ^a   Vöhringer, Paul A ^c,d   Jeunemaitre, Xavier ^e   Hopkins, Paul N ^f   Yao, Tham M ^a   Williams, Jonathan ^a   Adler, Gail K ^a   Williams, Gordon H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

adrenal cortex hormones; aldosterone; glucocorticoids; hypertension; sodium; statin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATORVASTATIN; CORTICOSTERONE; FLUINDOSTATIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ALDOSTERONE RELEASE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; EX VIVO STUDY; FEMALE; HEMODYNAMIC PARAMETERS; HIGH SODIUM INTAKE; HORMONE DETERMINATION; HUMAN; HYPERTENSION; IN VITRO STUDY; LABORATORY TEST; MALE; NONHUMAN; PRIORITY JOURNAL; SODIUM RESTRICTION; ZONA GLOMERULOSA; ADRENAL GLAND; ANIMAL; BLOOD; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RAT; SECRETION (PROCESS); WISTAR RAT;

ADRENAL GLANDS; ADULT; ALDOSTERONE; ANIMALS; DIABETES MELLITUS; DIET, SODIUM-RESTRICTED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; RATS; RATS, WISTAR;

EID: 84947289950     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016759     Document Type: Article

References (50)

1. Mann DM, Woodward M, Ye F, Krousel-Wood M, Muntner P. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169:1718-1720. doi: 10.1001/archinternmed.2009.296.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
3. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi: 10.1136/bmj.b2376.
4. Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014;20:1198-1215. doi: 10.1089/ars.2013.5430.
5. Liu PY, Lee PT, Chang WT, Tai YL, Chao TH, Lee CH, Li YH, Chen JH, Tsai LM, Liao JK. Evidence of pleiotropy by statins: leukocyte Rho kinase (ROCK) activity and pretreated statin before percutaneous coronary interventions are clinical vascular outcome predictors. Int J Cardiol. 2014;176:250-253. doi: 10.1016/j.ijcard.2014.06.059.
6. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566. doi: 10.1161/01.CIR.0000091404.09558.AF.
7. de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3:181-190. doi: 10.1016/S2213-8587(14)70246-3.
8. Ma S, Ma CC. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factorbeta superfamily. Cytokine Growth Factor Rev. 2011;22:167-175. doi: 10.1016/j.cytogfr.2011.05.004.
9. Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J. Effects of statin treatment on cardiac function in patients with chronic heart failure: a metaanalysis of randomized controlled trials. Clin Cardiol. 2011;34:117-123. doi: 10.1002/clc.20821.
10. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828-835. doi: 10.1016/j.jacc.2007.09.063.
11. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009;7:514-520. doi: 10.1111/j.1538-7836.2008.03235.x.
12. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49:792-798. doi: 10.1161/01. HYP.0000259737.43916.42.
13. Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J. 2010;74:818-826. doi: 10.1253/circj.CJ-10-0110.
14. Michalsen A, Lehmann N, Pithan C, Knoblauch NT, Moebus S, Kannenberg F, Binder L, Budde T, Dobos GJ. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease. Eur J Clin Nutr. 2006;60:478-485. doi: 10.1038/sj.ejcn.1602340.
15. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
16. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443. doi: 10.1056/NEJMoa0800742.
17. Lieb W, Pencina MJ, Jacques PF, Wang TJ, Larson MG, Levy D, Kannel WB, Vasan RS. Higher aldosterone and lower N-terminal proatrial natriuretic peptide as biomarkers of salt sensitivity in the community. Eur J Cardiovasc Prev Rehabil. 2011;18:664-673. doi: 10.1177/1741826710389406.
18. Durante A, Peretto G, Laricchia A, Ancona F, Spartera M, Mangieri A, Cianflone D. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 2012;18:981-1004. doi: 10.2174/138161212799436467.
19. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191-202. doi: 10.1093/eurheartj/ehr176.
20. Xanthakis V, Enserro DM, Murabito JM, Polak JF, Wollert KC, Januzzi JL, Wang TJ, Tofler G, Vasan RS. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. Circulation. 2014;130:1676-1683. doi: 10.1161/CIRCULATIONAHA.114.009273.
21. Drapala A, Sikora M, Ufnal M. Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins. J Renin Angiotensin Aldosterone Syst. 2014;15:250-258. doi: 10.1177/1470320314531058.
22. Chamarthi B, Williams JS, Williams GH. A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II. J Hypertens. 2010;28:1020-1026. doi: 10.1097/HJH.0b013e3283375974.
23. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos. 2002;30:1158-1163. doi: 10.1124/dmd.30.11.115.
24. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-125. doi: 10.1111/j.1472-8206.2004.00299.x.
25. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35:139-151. doi: 10.1111/j.1365-2710.2009.01085.x.
26. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. 2007;92:4472-4475. doi: 10.1210/jc.2007-1088.
27. Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013;61:886-893. doi: 10.1161/HYPERTENSIONAHA.111.00662.
28. Garg R, Rao AD, Baimas-George M, Hurwitz S, Foster C, Shah RV, Jerosch-Herold M, Kwong RY, Di Carli MF, Adler GK. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes. 2015;64:236-242. doi: 10.2337/db14-0670.
29. Pojoga L, Kolatkar NS, Williams JS, Perlstein TS, Jeunemaitre X, Brown NJ, Hopkins PN, Raby BA, Williams GH. Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Hypertension. 2006;48:892-900. doi: 10.1161/01.HYP.0000244688.45472.95.
30. Lin YC, Chiang CH, Chang LT, Sun CK, Leu S, Shao PL, Hsieh MC, Tsai TH, Chua S, Chung SY, Kao YH, Yip HK. Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine. 2013;62:341-351. doi: 10.1016/j.cyto.2013.04.003.
31. Zhang XS, Ren JH, Lu JP, Fan Y. Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors. J Cardiovasc Pharmacol. 2010;56:171-176. doi: 10.1097/FJC.0b013e3181e5f2e2.
32. Braley LM, Menachery AI, Brown EM, Williams GH. Comparative effect of angiotensin II, potassium, adrenocorticotropin, and cyclic adenosine 3′,5′-monophosphate on cytosolic calcium in rat adrenal cells. Endocrinology. 1986;119:1010-1019. doi: 10.1210/endo-119-3-1010.
33. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687-3692. doi: 10.1161/01. CIR.0000143085.86697.13.
34. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, Kim DS, Shin EK. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005;45:1088-1093. doi: 10.1161/01.HYP.0000166722.91714.ba.
35. Maejima Y, Nobori K, Ono Y, Adachi S, Suzuki J, Hirao K, Isobe M, Ito H; Heart Failure by Coadministration of Statin and Angiotensin-II Receptor Blocker (HF-COSTAR) Trial Investigators. Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial. Circ J. 2011;75:589-595. doi: 10.1253/circj.CJ-10-0804.
36. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134. doi: 10.1161/01. CIR.100.21.2131.
37. Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMGCoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther. 1990;12:410-420.
38. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18:1496-1502. doi: 10.1016/j.amjhyper.2005.05.022.
39. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008;29:2489-2496. doi: 10.1093/eurheartj/ehn383.
40. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009;150:2211-2219. doi: 10.1210/en.2008-1512.
41. Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens. 2013;31:820-829. doi: 10.1097/HJH.0b013e32835e8227.
42. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49:1234-1238. doi: 10.1053/meta.2000.7716a.
43. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286. doi: 10.1161/01.HYP.34.6.1281.
44. Nishikawa T, Matsuzawa Y, Suematsu S, Saito J, Omura M, Kino T. Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells. Arzneimittelforschung. 2010;60:445-451. doi: 10.1055/s-0031-1296310.
45. Toba H, Mitani T, Takahashi T, Imai N, Serizawa R, Wang J, Kobara M, Nakata T. Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes. Clin Exp Pharmacol Physiol. 2010;37:1064-1070. doi: 10.1111/j.1440-1681.2010.05436.x.
46. Ortega I, Cress AB, Wong DH, Villanueva JA, Sokalska A, Moeller BC, Stanley SD, Duleba AJ. Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells. Biol Reprod. 2012;86:1-9. doi: 10.1095/biolreprod.111.094714.
47. Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57. doi: 10.1186/1741-7015-11-57.
48. Juncos LI, Juncos LA, García NH. The antihypertensive actions of statins: modulation by salt intake. Am J Hypertens. 2012;25:1140-1148. doi: 10.1038/ajh.2012.105.
49. Drapala A, Aleksandrowicz M, Zera T, Sikora M, Skrzypecki J, Kozniewska E, Ufnal M. The effect of simvastatin and pravastatin on arterial blood pressure, baroreflex, vasoconstrictor, and hypertensive effects of angiotensin II in Sprague-Dawley rats. J Am Soc Hypertens. 2014;8:863-871. doi: 10.1016/j.jash.2014.09.008.
50. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, März W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237-1247. doi: 10.1093/eurheartj/ehq019.